Latest news with #AnthemBiosciencesLimited
Mint
2 days ago
- Business
- Mint
Anthem Biosciences IPO day 1 Live: GMP, subscription status, review, other details. Buy or not?
Anthem Biosciences IPO: The initial public offering (IPO) of Anthem Biosciences Limited has hit the Indian primary market today. The public issue will remain open until 16 July 2025. This means the book build issue will remain open from Monday to Wednesday. The company promoters have declared the Anthem Biosciences IPO price band at ₹ 540 to ₹ 570 per equity share. The company aims to raise ₹ 3,395 crore from this initial offer, which is entirely offer-for-sale (OFS). Anthem Biosciences IPO is proposed for listing on the BSE and the NSE. The company's shares are available in the grey market before the Anthem Biosciences IPO subscription opening. According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 1] Anthem Biosciences IPO GMP: According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 2] Anthem Biosciences IPO subscription date: The public issue has opened today and will remain open until 16 July 2025. 3] Anthem Biosciences IPO price: The company has declared a price band of ₹ 540 to ₹ 570 per equity share. 4] Anthem Biosciences IPO size: The company aims to raise ₹ 3,395 crore from this initial public offering (ipo), which is entirely offer-for-sale (OFS). Photo: Courtesy mintgenie 5] Anthem Biosciences IPO lot size: Bidders can apply in lots, and one lot will comprise 26 company shares. 6] Anthem Biosciences IPO allotment date: The most likely date for share allotment is 17 July 2025. 7] Anthem Biosciences IPO registrar: KFin Technologies Ltd has been appointed registrar of the public issue. 8] Anthem Biosciences IPO lead managers: JM Financial, Citigroup Global Markets, JP Morgan India, and Nomura Financial Advisors have been appointed lead managers of the public offer. 9] Anthem Biosciences IPO listing date: The most likely date for share debut is 21 July 2025. 10] Anthem Biosciences IPO review: Advising invstors to apply for the book-build issue, Arun Kejriwal, Founder of Kejriwal Research and Investment Services, said, "The company is a CRDMO – contract research development and manufacturing organization with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical entity and New Biological Entity Capabilities. The company reported revenues of ₹ 1,844.55 crores and a PAT of ₹ 451 crores for the year ended March 25. The net margins are a healthy 23.4%. The EPS is ₹ 8.04. The PE multiple on a fully diluted basis is at 67.16-70.90," adding, "The key takeaway from this offer for sale is that the promoter founder of the company would continue to hold over 52% of the company and is not selling a single share in the entirely an offer for sale issue. This is a big comforting factor for investors nowadays, who are very wary of the entire offer for sale issues." Anand Rathi has also assigned a 'subscribe' tag to the public issue, saying, "The company has shown a profitable track record against its peers and intends to maintain it by leveraging its integrated manufacturing and technological capabilities by focusing on building complex speciality ingredients, peptides, probiotics, etc. On valuation parse, based on the annualised FY25, it is seeking PE of 70.6 times, and the post-issue market cap comes at ₹ 3,18,673 Mn. With this, the issue is fairly priced. We believe the company has the potential to continue to grow its revenue and profitability ratios compared to its peers. Hence, we give a "SUBSCRIBE" rating for the issue." Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Indian Express
3 days ago
- Business
- Indian Express
Anthem Biosciences IPO subscription opens on July 14. Check price band, allotment date and more
Anthem Biosciences IPO: The three-day subscription for the initial public offering (IPO) of Anthem Biosciences Limited will open on July 14, Monday. The Anthem Biosciences IPO subscription will close on July 16 (Wednesday). As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at Rs 570 apiece, which is the upper end of the price band. This aggregates the transaction size to Rs 1,016 crore, reports PTI. Anthem Biosciences has raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to BSE. Anthem Biosciences IPO has fixed the price band at Rs 540 to Rs 570 per equity share. KFin Technologies Limited is the registrar of Anthem Biosciences IPO. The face value and tick size of Anthem Biosciences IPO is Rs 2 and Re 1, respectively. According to the details available, the Anthem Biosciences IPO will be July 17. Anthem Biosciences Limited's shares are proposed to be listed on NSE, and BSE. The listing will likely take place on July 21. JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers for the Anthem Biosciences IPO. HDFC Bank Limited and ICICI Bank Limited are the sponsor banks for the Anthem Biosciences IPO. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. (With inputs from PTI)
